{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:48:22Z","timestamp":1792450102489,"version":"4.5.0"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":99,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A wide spectrum of genomic events leading to dysregulated fibroblast growth factor receptor (FGFR) signaling have been reported across low-grade and high-grade glial\/glioneuronal tumors. These events include structural alterations, such as gene fusions and duplications, as well as recurrent mutations in FGFR1\u20133. Several FGFR-selective tyrosine kinase inhibitors (TKIs) have received regulatory approval for clinical use, and newer isoform-specific FGFR inhibitors are under investigation. Among pediatric patients with FGFR-altered low-grade gliomas (LGGs) enrolled in clinical trials with FGFR inhibitors, promising clinical efficacy regardless of alteration type (fusion or mutation) has been observed in a subset. In contrast, limited responses have been reported in adults with FGFR3\u2013TACC3 fused IDH-wild-type glioblastoma. FGFR inhibitor toxicities include hyperphosphatemia, diarrhea, skin, nail, and ocular toxicity. Importantly, in skeletally immature patients, bone toxicities, such as accelerated growth spurts, limb fractures, and scoliosis, have been reported and require close monitoring. Co-occurring genomic alterations in MAPK pathway signaling components downstream of FGFR may drive intrinsic and acquired resistance to FGFR inhibitors. Further preclinical studies in relevant models of FGFR-altered pediatric gliomas are needed to help inform the development of novel, more effective and less toxic treatment strategies, as well as the rational design of clinical trials.<\/jats:p>","DOI":"10.1093\/noajnl\/vdaf113","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:46:32Z","timestamp":1748418392000},"page":"ii31-ii40","source":"Crossref","is-referenced-by-count":2,"title":["FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-2402","authenticated-orcid":false,"given":"Sameer Farouk","family":"Sait","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3641-9287","authenticated-orcid":false,"given":"Tejus","family":"Bale","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7151-6528","authenticated-orcid":false,"given":"Matthias A","family":"Karajannis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"1","key":"2026042812483308600_CIT0001","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med."},{"issue":"8","key":"2026042812483308600_CIT0002","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med."},{"issue":"12","key":"2026042812483308600_CIT0003","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med."},{"issue":"9","key":"2026042812483308600_CIT0004","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-019-01142-9","article-title":"Erdafitinib: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs."},{"issue":"5","key":"2026042812483308600_CIT0005","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/1078-0432.CCR-22-2036","article-title":"FDA approval summary: pemigatinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2026042812483308600_CIT0006","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"2026042812483308600_CIT0007","doi-asserted-by":"crossref","first-page":"D165","DOI":"10.2741\/Klint","article-title":"Signal transduction by fibroblast growth factor receptors","volume":"4","author":"Klint","year":"1999","journal-title":"Front Biosci."},{"issue":"3","key":"2026042812483308600_CIT0008","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov"},{"issue":"5","key":"2026042812483308600_CIT0009","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer."},{"issue":"15","key":"2026042812483308600_CIT0010","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/0008-5472.CAN-21-0791","article-title":"Gene fusions create partner and collateral dependencies essential to cancer cell survival","volume":"81","author":"Gillani","year":"2021","journal-title":"Cancer Res."},{"issue":"13","key":"2026042812483308600_CIT0011","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Andr\u00e9","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2026042812483308600_CIT0012","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062011","article-title":"The fibroblast growth factor receptors in breast cancer: from oncogenesis to better treatments","volume":"21","author":"Sobhani","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"30","key":"2026042812483308600_CIT0013","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol."},{"issue":"1","key":"2026042812483308600_CIT0014","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2026042812483308600_CIT0015","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"2026042812483308600_CIT0016","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40478-020-00898-6","article-title":"FGFR- gene family alterations in low-grade neuroepithelial tumors","volume":"8","author":"Bale","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"6099","key":"2026042812483308600_CIT0017","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science."},{"issue":"4","key":"2026042812483308600_CIT0018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.18632\/oncotarget.137","article-title":"Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes","volume":"1","author":"Duncan","year":"2010","journal-title":"Oncotarget"},{"issue":"7687","key":"2026042812483308600_CIT0019","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature25171","article-title":"A metabolic function of FGFR3-TACC3 gene fusions in cancer","volume":"553","author":"Frattini","year":"2018","journal-title":"Nature."},{"issue":"24","key":"2026042812483308600_CIT0020","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-14-1337","article-title":"Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma","volume":"20","author":"Capelletti","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2026042812483308600_CIT0021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/onc.2011.235","article-title":"Disruption of Tacc3 function leads to in vivo tumor regression","volume":"31","author":"Yao","year":"2012","journal-title":"Oncogene."},{"issue":"14","key":"2026042812483308600_CIT0022","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","article-title":"Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma","volume":"21","author":"Di Stefano","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2026042812483308600_CIT0023","first-page":"855","article-title":"The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma","volume":"123","author":"Parker","year":"2013","journal-title":"J Clin Invest."},{"issue":"8","key":"2026042812483308600_CIT0024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tcb.2008.06.005","article-title":"The TACC proteins: TACC-ling microtubule dynamics and centrosome function","volume":"18","author":"Peset","year":"2008","journal-title":"Trends Cell Biol."},{"issue":"15","key":"2026042812483308600_CIT0025","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1073\/pnas.161259898","article-title":"Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways","volume":"98","author":"Hadari","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2026042812483308600_CIT0026","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0092-8674(00)80252-4","article-title":"A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras\/MAPK signaling pathway","volume":"89","author":"Kouhara","year":"1997","journal-title":"Cell."},{"issue":"5","key":"2026042812483308600_CIT0027","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/1541-7786.MCR-15-0497","article-title":"Oncogenic gene fusion FGFR3-TACC3 is regulated by tyrosine phosphorylation","volume":"14","author":"Nelson","year":"2016","journal-title":"Mol Cancer Res."},{"issue":"5","key":"2026042812483308600_CIT0028","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bpa.12563","article-title":"Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features","volume":"28","author":"Bielle","year":"2018","journal-title":"Brain Pathol."},{"issue":"1","key":"2026042812483308600_CIT0029","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s40478-020-01058-6","article-title":"Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions","volume":"8","author":"Mata","year":"2020","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"2026042812483308600_CIT0030","first-page":"1206","article-title":"Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas","volume":"19","author":"Granberg","year":"2017","journal-title":"Neuro Oncol"},{"issue":"3","key":"2026042812483308600_CIT0031","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-016-1639-9","article-title":"Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway","volume":"133","author":"Huse","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2026042812483308600_CIT0032","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1634\/theoncologist.2017-0242","article-title":"Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures","volume":"22","author":"Johnson","year":"2017","journal-title":"Oncologist."},{"issue":"6","key":"2026042812483308600_CIT0033","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet."},{"issue":"1","key":"2026042812483308600_CIT0034","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-020-02245-4","article-title":"Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY)","volume":"141","author":"Bale","year":"2021","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2026042812483308600_CIT0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-022-02430-7","article-title":"DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival","volume":"144","author":"Wu","year":"2022","journal-title":"Acta Neuropathol."},{"key":"2026042812483308600_CIT0036","doi-asserted-by":"crossref","first-page":"1307591","DOI":"10.3389\/fonc.2023.1307591","article-title":"Polymorphous low-grade neuroepithelial tumor of the young with FGFR3-TACC3 fusion mimicking high-grade glioma: case report and series of high-grade correlates","volume":"13","author":"Golub","year":"2023","journal-title":"Front Oncol."},{"key":"2026042812483308600_CIT0037","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun."},{"issue":"4","key":"2026042812483308600_CIT0038","first-page":"475","article-title":"FGFR-TACC gene fusions in human glioma","volume":"19","author":"Lasorella","year":"2017","journal-title":"Neuro Oncol"},{"issue":"10","key":"2026042812483308600_CIT0039","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00000478-200110000-00005","article-title":"Extraventricular neurocytomas: pathologic features and clinical outcome","volume":"25","author":"Brat","year":"2001","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"2026042812483308600_CIT0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00401-018-1882-3","article-title":"FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma","volume":"136","author":"Sievers","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2026042812483308600_CIT0041","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00401-016-1539-z","article-title":"Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology","volume":"131","author":"Qaddoumi","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2026042812483308600_CIT0042","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.18632\/oncotarget.12881","article-title":"Droplet digital PCR is a powerful technique to demonstrate frequent FGFR1 duplication in dysembryoplastic neuroepithelial tumors","volume":"8","author":"Fina","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"2026042812483308600_CIT0043","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet."},{"issue":"6","key":"2026042812483308600_CIT0044","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00401-016-1549-x","article-title":"Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors","volume":"131","author":"Rivera","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2026042812483308600_CIT0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ajhg.2016.02.006","article-title":"Mosaic activating mutations in FGFR1 cause encephalocraniocutaneous lipomatosis","volume":"98","author":"Bennett","year":"2016","journal-title":"Am J Hum Genet."},{"issue":"58","key":"2026042812483308600_CIT0046","doi-asserted-by":"crossref","first-page":"ra6","DOI":"10.1126\/scisignal.2000021","article-title":"The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations","volume":"2","author":"Lew","year":"2009","journal-title":"Sci Signal"},{"issue":"40","key":"2026042812483308600_CIT0047","doi-asserted-by":"crossref","first-page":"14344","DOI":"10.1073\/pnas.0507200102","article-title":"Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas","volume":"102","author":"Rand","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"43","key":"2026042812483308600_CIT0048","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1523\/JNEUROSCI.0993-04.2004","article-title":"Fibroblast growth factor receptor signaling promotes radial glial identity and interacts with Notch1 signaling in telencephalic progenitors","volume":"24","author":"Yoon","year":"2004","journal-title":"J Neurosci."},{"issue":"4","key":"2026042812483308600_CIT0049","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/ajmg.a.37017","article-title":"Grade II pilocytic astrocytoma in a 3-month-old patient with encephalocraniocutaneous lipomatosis (ECCL): case report and literature review of low grade gliomas in ECCL","volume":"167A","author":"Bieser","year":"2015","journal-title":"Am J Med Genet A."},{"issue":"3","key":"2026042812483308600_CIT0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00381-015-2847-7","article-title":"Encephalocraniocutaneous lipomatosis, a rare neurocutaneous disorder: report of additional three cases","volume":"32","author":"Kocak","year":"2016","journal-title":"Childs Nerv Syst."},{"issue":"4","key":"2026042812483308600_CIT0051","doi-asserted-by":"crossref","first-page":"E1165","DOI":"10.1227\/NEU.0b013e3181edb24c","article-title":"Papillary glioneuronal tumor present in a patient with encephalocraniocutaneous lipomatosis: case report","volume":"67","author":"Phi","year":"2010","journal-title":"Neurosurgery."},{"issue":"4","key":"2026042812483308600_CIT0052","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat Rev Cancer."},{"issue":"7","key":"2026042812483308600_CIT0053","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/NEN.0000000000000213","article-title":"KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in pilocytic astrocytomas","volume":"74","author":"Becker","year":"2015","journal-title":"J Neuropathol Exp Neurol."},{"issue":"2","key":"2026042812483308600_CIT0054","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5414\/NP300682","article-title":"Rosette-forming glioneuronal tumor with dissemination throughout the ventricular system: a case report","volume":"34","author":"Allinson","year":"2015","journal-title":"Clin Neuropathol."},{"issue":"6","key":"2026042812483308600_CIT0055","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.humpath.2008.11.010","article-title":"A rosette-forming glioneuronal tumor of the spinal cord: the first case of a rosette-forming glioneuronal tumor originating from the spinal cord","volume":"40","author":"Anan","year":"2009","journal-title":"Hum Pathol."},{"issue":"7","key":"2026042812483308600_CIT0056","doi-asserted-by":"crossref","first-page":"e101211","DOI":"10.1371\/journal.pone.0101211","article-title":"An individual patient data meta-analysis on characteristics and outcome of patients with papillary glioneuronal tumor, rosette glioneuronal tumor with neuropil-like islands and rosette forming glioneuronal tumor of the fourth ventricle","volume":"9","author":"Schlamann","year":"2014","journal-title":"PLoS One."},{"key":"2026042812483308600_CIT0057","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.wneu.2019.08.055","article-title":"Disseminated rosette-forming glioneuronal tumor with spinal drop metastasis, a uniquely aggressive presentation of rare tumor","volume":"132","author":"Silveira","year":"2019","journal-title":"World Neurosurg"},{"issue":"3","key":"2026042812483308600_CIT0058","first-page":"227","article-title":"Rosette-forming glioneuronal tumor in the pineal gland and the third ventricle: a case with radiological and clinical implications","volume":"2","author":"Xu","year":"2012","journal-title":"Quant Imag Med Surg"},{"issue":"3","key":"2026042812483308600_CIT0059","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00401-019-02038-4","article-title":"Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1","volume":"138","author":"Sievers","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2026042812483308600_CIT0060","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"7384","key":"2026042812483308600_CIT0061","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature."},{"issue":"1","key":"2026042812483308600_CIT0062","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00401-023-02651-4","article-title":"A new subtype of diffuse midline glioma, H3 K27 and BRAF\/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation","volume":"147","author":"Auffret","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2026042812483308600_CIT0063","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00401-024-02800-3","article-title":"Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance","volume":"148","author":"Stegat","year":"2024","journal-title":"Acta Neuropathol."},{"issue":"6","key":"2026042812483308600_CIT0064","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00401-023-02640-7","article-title":"Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations","volume":"146","author":"Roberts","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"62","key":"2026042812483308600_CIT0065","doi-asserted-by":"crossref","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Weiss","year":"2010","journal-title":"Sci Transl Med."},{"issue":"3","key":"2026042812483308600_CIT0066","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10549-009-0677-6","article-title":"Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate","volume":"123","author":"Shiang","year":"2010","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"2026042812483308600_CIT0067","first-page":"240","article-title":"Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells","volume":"12","author":"Ornitz","year":"1992","journal-title":"Mol Cell Biol."},{"issue":"23","key":"2026042812483308600_CIT0068","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41388-023-02705-7","article-title":"Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers","volume":"42","author":"Brown","year":"2023","journal-title":"Oncogene."},{"issue":"1","key":"2026042812483308600_CIT0069","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40478-021-01170-1","article-title":"Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs","volume":"9","author":"Georgescu","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"2026042812483308600_CIT0070","doi-asserted-by":"crossref","first-page":"e0231877","DOI":"10.1371\/journal.pone.0231877","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One."},{"issue":"12","key":"2026042812483308600_CIT0071","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov"},{"issue":"11","key":"2026042812483308600_CIT0072","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/1535-7163.MCT-14-0248","article-title":"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284\/Debio 1347, a novel selective FGFR inhibitor","volume":"13","author":"Nakanishi","year":"2014","journal-title":"Mol Cancer Ther."},{"issue":"11","key":"2026042812483308600_CIT0073","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1535-7163.MCT-16-0261","article-title":"E7090, a novel selective inhibitor of fibroblast growth factor receptors, displays potent antitumor activity and prolongs survival in preclinical models","volume":"15","author":"Watanabe Miyano","year":"2016","journal-title":"Mol Cancer Ther."},{"issue":"4","key":"2026042812483308600_CIT0074","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/acsmedchemlett.3c00006","article-title":"Discovery of futibatinib: the first covalent FGFR kinase inhibitor in clinical use","volume":"14","author":"Ito","year":"2023","journal-title":"ACS Med Chem Lett."},{"issue":"18","key":"2026042812483308600_CIT0075","doi-asserted-by":"crossref","first-page":"16737","DOI":"10.1021\/acs.jmedchem.4c01531","article-title":"Discovery of TYRA-300: first oral selective FGFR3 inhibitor for the treatment of urothelial cancers and achondroplasia","volume":"67","author":"Hudkins","year":"2024","journal-title":"J Med Chem."},{"issue":"8_Supplement","key":"2026042812483308600_CIT0076","doi-asserted-by":"crossref","first-page":"CT119","DOI":"10.1158\/1538-7445.AM2023-CT119","article-title":"Abstract CT119: a first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)","volume":"83","author":"Iyer","year":"2023","journal-title":"Cancer Res."},{"issue":"2","key":"2026042812483308600_CIT0077","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase i, dose-escalation and dose-expansion study","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol."},{"issue":"16","key":"2026042812483308600_CIT0078","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"18","key":"2026042812483308600_CIT0079","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A Phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2026042812483308600_CIT0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"issue":"16_suppl","key":"2026042812483308600_CIT0081","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2023.41.16_suppl.2051","article-title":"A phase 0 pharmacokinetic trigger trial of infigratinib in patients with recurrent high-grade glioma","volume":"41","author":"Sanai","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026042812483308600_CIT0082","article-title":"Debio1347, an oral FGFR inhibitor: results from a single-center study in pediatric patients with recurrent or refractory FGFR-altered gliomas","volume":"5","author":"Farouk Sait","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"20","key":"2026042812483308600_CIT0083","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1158\/1078-0432.CCR-24-0012","article-title":"Evaluating Debio 1347 in patients with FGFR fusion-positive advanced solid tumors from the FUZE multicenter, open-label, phase II basket trial","volume":"30","author":"Grivas","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"9829","key":"2026042812483308600_CIT0084","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet."},{"issue":"11","key":"2026042812483308600_CIT0085","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/mp3003144","article-title":"Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar","volume":"9","author":"Durmus","year":"2012","journal-title":"Mol Pharm."},{"issue":"2","key":"2026042812483308600_CIT0086","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ijc.31052","article-title":"The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors","volume":"142","author":"de Gooijer","year":"2018","journal-title":"Int J Cancer."},{"issue":"13","key":"2026042812483308600_CIT0087","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/bph.15034","article-title":"OATP1A\/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation","volume":"177","author":"Wang","year":"2020","journal-title":"Br J Pharmacol."},{"issue":"24","key":"2026042812483308600_CIT0088","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"21","key":"2026042812483308600_CIT0089","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.18632\/oncotarget.27600","article-title":"Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific pediatric neuro-oncology consortium study (PNOC-002)","volume":"11","author":"Nicolaides","year":"2020","journal-title":"Oncotarget"},{"issue":"7","key":"2026042812483308600_CIT0090","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026042812483308600_CIT0091","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2159-8290.CD-24-0417","article-title":"Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy","volume":"15","author":"Febres-Aldana","year":"2025","journal-title":"Cancer Discov"},{"issue":"1","key":"2026042812483308600_CIT0092","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41698-021-00204-0","article-title":"Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer","volume":"5","author":"Nakamura","year":"2021","journal-title":"npj Precis Oncol."},{"issue":"8","key":"2026042812483308600_CIT0093","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"issue":"16_suppl","key":"2026042812483308600_CIT0094","doi-asserted-by":"crossref","first-page":"10007","DOI":"10.1200\/JCO.2023.41.16_suppl.10007","article-title":"Erdafitinb in patients with FGFR-altered tumors: results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B)","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026042812483308600_CIT0095","doi-asserted-by":"crossref","first-page":"e2100371","DOI":"10.1200\/PO.21.00371","article-title":"Activity of pemigatinib in pilocytic astrocytoma and FGFR1(N546K) mutation","volume":"6","author":"Capone","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"2026042812483308600_CIT0096","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med."},{"issue":"17_supplement_2","key":"2026042812483308600_CIT0097","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1212\/WNL.0000000000203833","article-title":"Pemigatinib for previously treated central nervous system tumors with activating FGFR mutations or translocations: results from FIGHT-207 (S17.004)","volume":"100","author":"Spanggaard","year":"2023","journal-title":"Neurology."},{"key":"2026042812483308600_CIT0098","doi-asserted-by":"crossref","first-page":"e30410","DOI":"10.1002\/pbc.30410","article-title":"Slipped capital femoral epiphyses: a major on-target adverse event associated with FGFR tyrosine kinase inhibitors in pediatric patients","volume":"70","author":"Farouk Sait","year":"2023","journal-title":"Pediatr Blood Cancer."},{"issue":"10","key":"2026042812483308600_CIT0099","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/neuonc\/noac035","article-title":"Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients","volume":"24","author":"Miller","year":"2022","journal-title":"Neuro Oncol"},{"issue":"Supplement_3","key":"2026042812483308600_CIT0100","doi-asserted-by":"crossref","first-page":"vi20","DOI":"10.1093\/neuonc\/noz175.076","article-title":"OS10. 6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study","volume":"21","author":"Lassman","year":"2019","journal-title":"Neuro Oncol."},{"issue":"2","key":"2026042812483308600_CIT0101","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1\u20134 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discovery"},{"issue":"Supplement_15","key":"2026042812483308600_CIT0102","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1200\/JCO.2020.38.15_suppl.360","article-title":"Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion","volume":"38","author":"Cleary","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026042812483308600_CIT0103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med."},{"issue":"12","key":"2026042812483308600_CIT0104","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2026042812483308600_CIT0105","doi-asserted-by":"crossref","first-page":"101204","DOI":"10.1016\/j.xcrm.2023.101204","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep Med"},{"issue":"2","key":"2026042812483308600_CIT0106","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture","year":"2021","journal-title":"Oncologist."},{"issue":"3","key":"2026042812483308600_CIT0107","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/cge.14455","article-title":"CATSHL syndrome, a new family and phenotypic expansion","volume":"105","author":"Cannova","year":"2024","journal-title":"Clin Genet."},{"issue":"3","key":"2026042812483308600_CIT0108","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3171\/2019.12.JNS192155","article-title":"Association of the FGFR1 mutation with spontaneous hemorrhage in low-grade gliomas in pediatric and young adult patients","volume":"134","author":"Ishi","year":"2021","journal-title":"J Neurosurg."},{"issue":"1","key":"2026042812483308600_CIT0109","first-page":"vdae074","article-title":"Fibroblast growth factor receptor 1 gene mutation as a potential risk factor for spontaneous intracranial hemorrhage in pediatric low-grade glioma patients","volume":"6","author":"Gonzalez-Vega","year":"2024","journal-title":"Neurooncol Adv."},{"issue":"Supplement_4","key":"2026042812483308600_CIT0110","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1093\/neuonc\/noae064.398","article-title":"Report on pediatric brain tumor consortium (Pbtc)-029b, a prospective phase 2 clinical trial of selumetinib in treating young patients with recurrent\/progressive low-grade glioma: new results on strata 2, 5, and 6 with updated long-term survival outcomes on strata 1, 3, and 4","volume":"26","author":"Fangusaro","year":"2024","journal-title":"Neuro Oncol."},{"issue":"1","key":"2026042812483308600_CIT0111","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"Perreault","year":"2019","journal-title":"BMC Cancer"},{"issue":"Supplement_5","key":"2026042812483308600_CIT0112","doi-asserted-by":"crossref","first-page":"i58","DOI":"10.1093\/neuonc\/noad073.224","article-title":"Treatment of two pediatric fgfr-altered lowgrade glioneuronal tumors with Mek inhibition","volume":"25","author":"Lazow","year":"2023","journal-title":"Neuro Oncol."},{"issue":"Supplement_1","key":"2026042812483308600_CIT0113","doi-asserted-by":"crossref","first-page":"i99","DOI":"10.1093\/neuonc\/noac079.360","article-title":"The influence of different Fgfr1 alterations on pediatric low-grade glioma tumor biology and targeted therapy response","volume":"24","author":"Morin","year":"2022","journal-title":"Neuro-Oncology."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf113\/67301696\/vdaf113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/Supplement_2\/ii31\/67301696\/vdaf113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/Supplement_2\/ii31\/67301696\/vdaf113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:48:51Z","timestamp":1777394931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/8\/Supplement_2\/ii31\/8514393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":113,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf113","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,12,2]]}}}